Compare JPMorgan Nasdaq Equity Premium Income ETF (JEPQ) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JPMorgan Nasdaq Equity Premium Income ETF vs Neurocrine Biosciences Inc — how do they compare? JPMorgan Nasdaq Equity Premium Income ETF trades at $59.64, while Neurocrine Biosciences Inc trades at $179 (market cap $17.40B). The key difference: Neurocrine Biosciences Inc is trading nearer its 52-week high, JPMorgan Nasdaq Equity Premium Income ETF nearer its low. Which is the better fit depends on your goals.
| JEPQ | NBIX | |
|---|---|---|
Sector | Income / Options Overlay | Health |
52-Week High | $61.46 | $180.55 |
52-Week Low | $53.77 | $123.10 |
Market Cap | — | $17.40B |
Enterprise Value | — | $16.49B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About JPMorgan Nasdaq Equity Premium Income ETF
JEPQ seeks to provide monthly income and exposure to the Nasdaq-100 Index with less volatility. It uses a methodology that combines high-growth tech stocks with an options strategy to capture income.
Read more on JEPQ →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
